Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ARWR with free AI briefings, catalyst countdowns, and dilution alerts.

ARWR · ARROWHEAD PHARMACEUTICALS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.2B Cash on Hand
19.4mo Cash Runway
11.4% Short Interest
$105.86 Analyst Target (14)
Follow ARWR by email Get an email when ARWR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ARWR, unsubscribe in one click. Privacy

📣 What ARWR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Plozasiran
FDA approved Nov 2025 · Redemplo
Severe Hypertriglyceridemia Phase 3 · NCT06880770 Recruiting
Zodasiran Homozygous Familial Hypercholesterolemia Phase 3 · NCT07037771 Active not recruiting
3-Hydroxy-3-Methylglutaryl-Coenzyme A Intracerebral Hemorrhage Phase 3 · NCT03936361 Recruiting
Tenofovir Disoproxil Hepatitis B Phase 2 · NCT02577029 Terminated
Tenofovir Hepatitis B Phase 2 · NCT02604199 Terminated
JNJ-56136379 Hepatitis B Phase 1/2 · NCT03365947 Completed
ARO-MMP7 Inhalation Solution Idiopathic Pulmonary Fibrosis Phase 1/2 · NCT05537025 Completed
Fazirsiran Alpha 1-Antitrypsin Deficiency Phase 2 · NCT03945292 Completed
Chlorpheniramine Polistirex Hepatitis B, Chronic Phase 2 · NCT02065336 Terminated
ARO-RAGE Asthma Phase 2 · NCT07241546 Recruiting
ARO-MUC5AC Asthma Phase 1/2 · NCT05292950 Terminated
ARO-ANG3 Mixed Dyslipidemia Phase 2 · NCT04832971 Completed
Histamine-1 Receptor Antagonist Hepatitis B Phase 2 · NCT02604199 Terminated
ARC-520 Hepatitis B, Chronic Phase 2 · NCT02065336 Terminated
ARC-AAT Injection Alpha-1 Antitrypsin Deficiency Phase 2 · NCT02900183 Withdrawn
ARO-ALK7 Obesity Phase 1/2 · NCT06937203 Recruiting

Also used in these trials (approved or third-party drugs, not ARWR's own candidates): Ferrous Sulfate, Iron Sucrose, Tirzepatide, Peginterferon Alfa-2A, Entecavir, Diphenhydramine Hydrochloride, Acetaminophen.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ARWR holds $1.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $184.9M/quarter from operations, an estimated runway of 19.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 33 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARWR files for a raise →

👥 Who Owns ARWR

Insiders 4.3% Institutions (654 holders) 85.4% Public and other holders 10.3%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 14,232,545 10.07% 2026-06-30
Avoro Capital Advisors LLC Institution (13G, 5%+) 13,823,383 9.78% 2026-06-30
FMR LLC Institution (13G, 5%+) 9,307,350 6.58% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 7,081,293 5.01% 2026-03-31
Vanguard Portfolio Management LLC Institution (13F) 6,210,955 4.39% 2026-09-30
State Street Corporation Institution (13F) 6,122,271 4.33% 2026-09-30
Vestal Point Capital, LP Institution (13F) 4,815,000 3.41% 2026-09-30
Invesco Ltd. Institution (13F) 3,825,146 2.71% 2026-09-30
Christopher Richard Anzalone
Chief Executive Officer, Director
Insider 3,792,739 2.68% 2026-01-02
Geode Capital Management, LLC Institution (13F) 3,458,467 2.45% 2026-09-30
Patrick O'Brien
COO
Insider 547,408 0.39% 2026-01-06
Kenneth Allen Myszkowski
Chief Financial Officer
Insider 455,433 0.32% 2025-01-04

Share count 141,368,004 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-18
filed 2026-08-20
OLUKOTUN ADEOYE Y
Sale (S) 2,000 $86.96 31,600
2026-08-18
filed 2026-08-20
PERRY MICHAEL S
Sale (S) 11,600 $87.30 111,459
2026-05-12
filed 2026-05-14
Lu Hongbo
Sale (S) 2,970 $76.88 52,012
2026-04-23
filed 2026-04-24
Hamilton James C
Sale (S) 10,000 $75.00 226,958
2026-04-22
filed 2026-04-24
Apel Daniel Joseph
Sale (S) 8,730 $71.92 162,905

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-11-18 — NDA +9.1% +0.8% +10.2%

Browse all historical PDUFA outcomes →

Get the full ARWR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARWR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.